News | February 27, 2024
Kilitch Drug India's subsidiary wins tender in Ethiopia
The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to US$ 9.13 million
The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to US$ 9.13 million
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
These re-agent and diagnostic test kits come with 99.7% accuracy
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
